Evidence map›Paper›PMID 25388006›Full record

ArticleEuropean journal of human genetics : EJHG2015

Quantification of mutant E-cadherin using bioimaging analysis of in situ fluorescence microscopy. A new approach to CDH1 missense variants.

João Miguel Sanches, Joana Figueiredo, Martina Fonseca, Cecília Durães, Soraia Melo, Sofia Esménio, Raquel Seruca

Open access · hybridAbstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Review
  3. GermlineCancers · 2021
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Germline mutations in hereditary diffuse gastric cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2018
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

João Miguel SanchesInstitute for Systems and Robotics and Department of Bioengineering from the Instituto Superior Técnico, Technical University of Lisbon, Lisbon, Portugal.
Joana FigueiredoDepartment of Cancer Genetics, IPATIMUP - Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal.
Martina FonsecaInstitute for Systems and Robotics and Department of Bioengineering from the Instituto Superior Técnico, Technical University of Lisbon, Lisbon, Portugal.
Cecília DurãesDepartment of Cancer Genetics, IPATIMUP - Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal.
Soraia MeloDepartment of Cancer Genetics, IPATIMUP - Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal.
Sofia EsménioInstitute for Systems and Robotics and Department of Bioengineering from the Instituto Superior Técnico, Technical University of Lisbon, Lisbon, Portugal.
Raquel Seruca1] Department of Cancer Genetics, IPATIMUP - Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal [2] Faculty of Medicine of the University of Porto, Porto, Portugal.
Universidade do Porto · PTUniversity of Lisbon · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Missense mutations result in full-length proteins containing an amino acid substitution that can be neutral or deleterious, interfering with the normal conformation, localization, and function of a protein. A striking example is the presence of CDH1 (E-cadherin gene) germline missense variants in hereditary diffuse gastric cancer (HDGC), which represent a clinical burden for genetic counseling and surveillance of mutation carriers and their families. CDH1 missense variants can compromise not only the function of E-cadherin but also its expression pattern. Here, we propose a novel method to characterize E-cadherin signature in order to identify cases with E-cadherin deregulation and functional impairment. The strategy includes a bioimaging pipeline to quantify the expression level and characterize the distribution of the protein from in situ immunofluorescence images. The algorithm computes 1D (dimension intensity) radial and internuclear fluorescence profiles to generate expression outlines and 2D virtual cells representing a typical cell within the populations analyzed. Using this new approach, we verify that cells expressing mutant forms of E-cadherin display fluorescence profiles distinct from those of the wild-type cells. Mutant proteins showed a significantly decrease of fluorescence intensity at the membrane and often abnormal expression peaks in the cytoplasm, reflecting the underlying molecular mechanism of trafficking deregulation. Our results suggest employing this methodology as a complementary approach to evaluate the pathogenicity of E-cadherin missense variants. Moreover, it can be applied to a wide range of proteins and, more importantly, to diseases characterized by aberrant protein expression or trafficking deregulation.

Indexed as

Genetic Predisposition to DiseaseCadherinsCell LineGenetic CounselingHumansIn Situ Hybridization, FluorescenceMicroscopy, FluorescenceMolecular ImagingMutation, MissenseStomach NeoplasmsCadherins

Identifiers

PMID25388006
PMCPMC4795115
OpenAlexW2140105836

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.